Drugs for Viral Hepatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 274)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Atorvastatin |
Approved |
Phase 4 |
|
134523-00-5 |
60823 |
Synonyms:
(3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid
(3R,5R)-7-[3-(anilinocarbonyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid
(betaR,deltaR)-2-(p-Fluorophenyl)-beta,delta-dihydroxy-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrole-1-heptanoic acid
(R-(R*,r*))-2-(4-fluorophenyl)-b,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoate
(R-(R*,r*))-2-(4-fluorophenyl)-b,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid
(R-(R*,r*))-2-(4-fluorophenyl)-b,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoate
(R-(R*,r*))-2-(4-fluorophenyl)-b,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid
(R-(R*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoate
(R-(R*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid
(R-(R*,R*))-2-(4-Fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid
(R-(R*,r*))-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoate
(R-(R*,r*))-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid
134523-00-5
134523-03-8
7-[2-(4-FLUORO-PHENYL)-5-ISOPROPYL-3-PHENYL-4-PHENYLCARBAMOYL-PYRROL-1-YL]- 3,5-DIHYDROXY-HEPTANOIC ACID
7-[2-(4-fluoro-PHENYL)-5-isopropyl-3-phenyl-4-phenylcarbamoyl-pyrrol-1-yl]-3,5-dihydroxy-heptanoate
7-[2-(4-fluoro-PHENYL)-5-isopropyl-3-phenyl-4-phenylcarbamoyl-pyrrol-1-yl]-3,5-dihydroxy-heptanoIC ACID
AC-15611
AC1L1TZT
AC1Q1OZQ
AKOS000281127
Anhydrous, atorvastatin calcium
Atogal
Atorlip
Atorpic
atorvastatin
Atorvastatin
Atorvastatin (INN)
Atorvastatin [INN:BAN]
Atorvastatin acid
Atorvastatin calcium
Atorvastatin calcium anhydrous
Atorvastatin calcium hydrate
Atorvastatin calcium trihydrate
Atorvastatin, calcium salt
atorvastatina
Atorvastatina
atorvastatine
Atorvastatine
atorvastatinium
atorvastatinum
Atorvastatinum
atrovastin
BIDD:GT0336
C06834
C33H35FN2O5
|
Calcium anhydrous, atorvastatin
Calcium hydrate, atorvastatin
Calcium salt atorvastatin
Calcium trihydrate, atorvastatin
Calcium, atorvastatin
Cardyl
CCRIS 7159
CHEBI:39548
CHEMBL1487
CI 981
CID60823
D07474
DB01076
Faboxim
Hipolixan
HSDB 7039
Hydrate, atorvastatin calcium
Lipitor
Lipitor (TN)
Lipitor(TM)
Lipotropic
Lipovastatinklonal
Liprimar
Liptonorm
Lowden
LS-136975
MolPort-000-883-773
NCGC00159458-02
nchembio.301-comp8
Normalip
Sincol
Sortis
Sortis (TN)
Sotis
Torvacard
Torvast
Totalip
Tozalip
Trihydrate, atorvastatin calcium
Tulip
UNII-A0JWA85V8F
Vastina
Xanator
Xarator
Xavator
Zurinel
|
|
2 |
|
Peginterferon alfa-2a |
Approved, Investigational |
Phase 4 |
|
198153-51-4 |
5360545 |
Synonyms:
198153-51-4
D02747
Pegasys
Pegasys (TN)
PEG-IFN alfa-2A
Peginterferon alfa-2a
PEG-Interferon alfa-2A
|
Peginterferon alfa-2a (genetical recombination)
Peginterferon alfa-2a (genetical recombination) (JAN)
Peginterferon alfa-2a (USAN/INN)
Pegylated Interfeaon alfa-2A
Pegylated interferon alfa-2a
Pegylated interferon alpha-2a
Pegylated-interferon alfa 2a
|
|
3 |
|
Milk thistle |
Approved, Experimental, Investigational |
Phase 4 |
|
65666-07-1 |
|
Synonyms:
822i9lej7s
Cardui Mariae Fructus
Carduus Marianus
Carduus Marianus Preparation
Carduus Marianus Seed
Fruit of Silybum Marianum
Holy Thistle Seed
Lady's Thistle Seed
Mariana Mariana Seed
Mary's Thistle Seed
Milk Thistle Extract
Milk Thistle Fruit
Milk Thistle Seed
Milk Thistle Seed Extract
|
Milk Thistle Silymarin
Milkthistle Fruit (Silybum Marianum L. Gaertner)
Saint Mary's Thistle Extract
Shuifeiji
Silybi Fructus
Silybi Mariani Fructus (Silybum Marianum L. Gaertner)
Silybum Marianum Dry Fruit
Silybum Marianum Dry Fruit Extract
Silybum Marianum Extract
Silybum Marianum Fruit
Silybum Marianum Fruit Extract
Silybum Marianum Seed
Silybum Marianum Seed Extract
|
|
4 |
|
Lamivudine |
Approved, Investigational |
Phase 4 |
|
134678-17-4 |
60825 |
Synonyms:
(-)-(2'R,5'S)-1-[2'-Hydroxymethyl-5'-(1,3-oxathiolanyl)]cytosine
(-)-1-((2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine
(-)-1-[(2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
(-)-2'-Deoxy-3'-thiacytidine
(-)-BCH 189
(-)-BCH-189
(-)-beta-L-2',3'-Dideoxy-3'-thiacytidine
(-)NGPB-21
(-)-SddC
(+/-) (Cis)-1-[2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
(+/-)-3TC
(+/-)-BCH-189
(+/-)-SddC
(2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one
.beta.-L-(-)-2',3'-dideoxy-3'-thiacytidine & Sho-Saiko-To
134678-17-4
2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2R,5S)
2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2R,5S) & Galanthus Nivalis Agglutinin (GNA)
2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2R,5S) & Hippeastrum hybrid agglutinin( HHA)
2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (+/-) (Cis)
2',3' Dideoxy 3' thiacytidine
2',3'-Dideoxy-3'-thiacytidine
3TC
3TC & GNA
3TC & SST
3TC (AIDS INITIATIVE) (AIDS INITIATIVE)
3TC and NV-01
3TC, Zeffix, Heptovir, Epivir, Epivir-HBV, Lamivudine
3'-Thia-2',3'-dideoxycytidine
480434-79-5
4-Amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone
4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one
4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one
AC-1416
AC1L1TZZ
AC1Q6C34
BCH 189
BCH189
BCH-189
BCH-790
beta-L-2',3'-Dideoxy-3'-thiacytidine
beta-L-3'-Thia-2',3'-dideoxycytidine
BIDD:GT0033
Bio-0652
b-L-2',3'-Dideoxy-3'-thiacytidine
b-L-3'-Thia-2',3'-dideoxycytidine
C07065
C8H11N3O3S
CCRIS 9274
CHEBI:133986
CHEMBL141
CID60825
CPD000466319
D00353
D019259
|
DB00709
DRG-0126
DTHC
Epivir
Epivir (TN)
Epivir(TM)
Epivir-HBV
Epzicom
FT-0082667
GG-714
GR 109714X
GR109714X
GR-109714X
Hepitec
Heptivir
Heptodin
Heptovir
HHA & 3TC
HHA & Lamivudine
HMS2051D21
HSDB 7155
L0217
Lamivir
Lamivudin
Lamivudina
lamivudine
Lamivudine
Lamivudine & GNA
Lamivudine (JAN/USP/INN)
Lamivudine [Usan:Ban:Inn]
Lamivudine [USAN:BAN:INN]
Lamivudine [USAN:INN:BAN]
Lamivudine, (2S-cis)-isomer
Lamivudine, (2S-cis)-Isomer
Lamivudinum
LMV
LS-2107
MLS000759424
MLS001424097
MolPort-002-507-347
NCGC00159341-03
NCGC00159341-04
NSC620753
S1706_Selleck
SAM001246582
SAM002589994
SMR000466319
STK801940
UNII-2T8Q726O95
Zeffix
Zefix
ZINC00012346
β-L-2',3'-dideoxy-3'-thiacytidine
β-L-3'-thia-2',3'-dideoxycytidine
|
|
5 |
|
Maraviroc |
Approved, Investigational |
Phase 4 |
|
376348-65-1 |
3002977 |
Synonyms:
376348-65-1
4,4-difluoro-N-((1S)-3-(exo-3-(3-Isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo(3.2.1)oct-8-yl)-1-phenylpropyl)cyclohexanecarboxamide
4,4-Difluoro-N-((1S)-3-(exo-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo(3.2.1)oct-8-yl)-1-phenylpropyl)cyclohexanecarboxamide
4,4-difluoro-N-[(1S)-3-[(1R,5S)-3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide
674782-29-7
AC1MHEFQ
AC-558
Celsentri
Celsentri(TM)
CHEBI:537583
CHEMBL1201187
CHEMBL256907
CID3002977
DB04835
exo-4,4-Difluoro-N-[3-[3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]oct-8-yl]-1(S)-phenylpropyl]cyclohexanecarboxamide
Isopropyl, 4,4-difluoro-N-((1S)-3-{(1R,3s,5S)-3-(3-methyl-5-(propan-2-yl)-4H-1,2,4-triazol-4-yl)-8-azabicyclo(3.2.1)octan-8-yl}-1-phenylpropyl)cyclohexanecarboxamide
|
LS-182818
maraviroc
Maraviroc
Maraviroc [USAN]
Maravirocum
MVC
Pfizer brand OF maraviroc
PRO 140 & Maraviroc
PRO 140 (Anti-CCR5 monoclonal antibody) & exo-4,4-Difluoro-N-[3-[3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]oct-8-yl]-1(S)-phenylpropyl]cyclohexanecarboxamide
Selzentry
Selzentry(TM)
UK 427857
UK-427,857
UK-427,857 maraviroc (MVC)
UK-427857
UNII-MD6P741W8A
|
|
6 |
|
Iron |
Approved, Experimental |
Phase 4 |
|
15438-31-0, 7439-89-6 |
27284 23925 |
Synonyms:
02583_FLUKA
12310_ALDRICH
12310_RIEDEL
129048-51-7
14067-02-8
161135-39-3
190454-13-8
195161-83-2
199281-22-6
209309_ALDRICH
209309_SIAL
255637_ALDRICH
266213_ALDRICH
266256_ALDRICH
267945_ALDRICH
267953_ALDRICH
26Fe
338141_ALDRICH
356808_ALDRICH
356824_ALDRICH
356832_ALDRICH
39344-71-3
3ZhP
413054_ALDRICH
443783-52-6
44890_ALDRICH
44890_FLUKA
675141-17-0
70884-35-4
73135-38-3
7439-89-6
8011-79-8
8053-60-9
AC1L2N38
Ancor B
Ancor en 80/150
armco Iron
Armco iron
Atomel 28
Atomel 300M200
Atomel 500M
Atomel 95
Atomiron 44MR
Atomiron 5M
Atomiron AFP 25
Atomiron AFP 5
ATW 230
ATW 432
C00023
C3518_SIAL
C3518_SIGMA
Carbonyl iron
CCRIS 1580
CHEBI:18248
CID23925
Copy Powder CS 105-175
D007501
DB01592
Diseases (animal), iron overload
Diseases, iron overload
DSP 1000
DSP 128B
DSP 135
DSP 135C
DSP 138
Ed-In-Sol
EF 1000
EF 250
EFV 200/300
EFV 250
EFV 250/400
EINECS 231-096-4
Eisen
Electrolytic iron
F 60 (metal)
Fe
FE
FE (II) ion
Fe(2+)
Fe(II)
Fe1+
Fe2+
Fe-40
|
fer
Feronate
Ferretts
Ferro-Caps
Ferro-Time
Ferrous ion
ferrous iron
Ferrousal
Ferrovac e
Ferrovac E
Ferrum
Ferrum metallicum
FT 3 (element)
GS 6
Hematite
Hemocyte
HF 2 (element)
hierro
Hierro
HL (iron)
Hoeganaes ATW 230
Hoeganaes EH
HQ (metal)
HS (iron)
HS 4849
HSDB 604
Infed
IRMM524A_FLUKA
IRMM524B_FLUKA
IRON
Iron (Fe)
Iron (Fe1+)
Iron ion (Fe+)
Iron ion(1+)
Iron ion(2+)
Iron monocation
Iron powder
Iron standard for AAS
Iron(1+)
Iron(1+) ion
Iron(2+)
Iron(2+) ion
Iron(II) ion
Iron(III) nitrate solution
Iron, carbonyl
Iron, electrolytic
Iron, elemental
Iron, ion (Fe1+)
Iron, ion (Fe1+) (8CI,9CI)
Iron, ion (Fe2+)
Iron, reduced
Limonite
LOHA
LS-3196
Magnetite
Malleable iron
Metopirone
Metyrapone
MolPort-003-925-001
NC 100
PZh1M1
PZh-1M3
PZh-2
PZh2M
PZH2m
PZh2M1
PZh2M2
PZh3
PZh3M
PZh4M
PZhO
PZHO
Reduced iron
Remko
Siderol
Suy-b 2
SUY-B 2
Taconite
UNII-E1UOL152H7
Venofer
Vitedyn-Slo
Wrought iron
Yieronia
|
|
7 |
|
Halofantrine |
Approved |
Phase 4 |
|
69756-53-2 |
37393 |
Synonyms:
(+-)-Halofantrine hydrochloride
(1)-Halofantrine
1-(1,3-Dichloro-6-trifluoromethyl-9-phenanthryl)-3-(di-n-butylamino)propanol hydrochloride
1-(1,3-dichloro-6-trifluoromethyl-9-phenanthryl)-3-di(n-butyl)aminopropanol HCl
1-(1,3-dichloro-6-Trifluoromethyl-9-phenanthryl)-3-di(N-butyl)aminopropanol HCL
1,3-Dichloro-.alpha.-[2-(dibutylamino)ethyl]-6- (trifluoromethyl)-9-phenathrenemethanol
1,3-Dichloro-.alpha.-[2-(dibutylamino)ethyl]-6-(trifluoromethyl)-9-phenanthrene-methanol
1,3-Dichloro-6-trifluoromethyl-9-(3-(dibutylamino)-1-hydroxypropyl)phenanthrene HCl
1,3-Dichloro-alpha-(2-(dibutylamino)ethyl)-6-(trifluoromethyl)-9-phenanthrenemethanol hydrochloride
1,3-Dichloro-alpha-(2-(dibutylamino)ethyl)-6-(trifluoromethyl)phenanthren-1-methanol hydrochloride
106927-11-1
3-(Dibutylamino)-1-(1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl)propan-1-ol hydrochloride
3-(dibutylamino)-1-[1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl]propan-1-ol
3-(dibutylamino)-1-[1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl]propan-1-ol hydrochloride
36167-63-2
66051-63-6
69756-53-2
9-(3-(dibutylamino)-1-hydroxypropyl)-1,3-dichloro-6-(trifluoromethyl)phenanthrene hydrochloride
9-Phenanthrenemethanol, 1,3-dichloro-.alpha.-[2-(dibutylamino)ethyl]-6-(trifluoromethyl)-(1)
9-Phenanthrenemethanol, 1,3-dichloro-alpha-(2-(dibutylamino)ethyl)-6-(trifluoromethyl)-, hydrochloride
9-Phenanthrenemethanol, 1,3-dichloro-alpha-(2-(dibutylamino)ethyl)-6-(trifluoromethyl)-,hydrochloride
AB00514703
AC1L1XMK
AC1L1XMN
AC1Q4K45
AC-481
BPBio1_001366
BSPBio_001241
C26H30Cl2F3NO.HCl
CHEBI:252728
CHEMBL1107
CHEMBL1200901
CID37392
CID37393
D02485
DB01218
dl-WR 171669
EINECS 252-895-4
|
FT-0082696
Halfan
Halfan (TN)
Halofantrina
Halofantrine
Halofantrine [USAN]
Halofantrine HCl
Halofantrine hydrochloride
HALOFANTRINE HYDROCHLORIDE
Halofantrine hydrochloride (USAN)
Halofantrine Hydrochloride [USAN]
Halofantrino
Halofantrino [Spanish]
Halofantrinum
HMS1571O03
I14-2822
LS-102675
LS-187198
MLS002154111
MolPort-005-940-418
MolPort-005-942-171
NCGC00179250-01
NCI60_002593
Prestwick0_001031
Prestwick1_001031
Prestwick2_001031
Prestwick3_001031
SK&F-102866
SMR001233418
SPBio_003092
UNII-H77DL0Y630
UNII-Q2OS4303HZ
WR 171,699
WR 171669
WR-171,669
WR-171669
WR-171699
|
|
8 |
|
Tacrolimus |
Approved, Investigational |
Phase 4 |
|
104987-11-3 |
445643 439492 6473866 |
Synonyms:
(-)-FK 506
(3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,19-dihydroxy-3-{(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl}-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(prop-2-en-1-yl)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-3H-15,19-epoxypyrido[2,1-c][1,4]oxazacyclotricosine-1,7,20,21(4H,23H)-tetrone
104987-11-3
109581-93-3 (Hydrate)
15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(23H)-tetrone,
3S-[3R*[E(1S*,3S*,4S*)],4S*,5R*,8S*,9E,12R*,14R*,15S*,16R*,18S*,19S*,26aR*]]-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5, 19-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-15,19-epoxy-3H-pyrido[2,1-c] [1,4] oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone
8-DEETHYL-8-[BUT-3-ENYL]-ASCOMYCIN
AC-1182
AC1L1K7H
AC1L97GB
AC1L9IBU
Advagraf
AKOS005145901
Ambap104987-11-3
Ambap5429
Anhydrous tacrolimus
Anhydrous, tacrolimus
BCBcMAP01_000194
Bio-0921
Bio2_000470
Bio2_000950
BRD-K35452788-001-02-1
BSPBio_001279
BSPBio-001279
C01375
C44H69NO10
CCRIS 7124
CHEBI:100924
CHEBI:61049
CHEMBL1200738
CID11158639
CID11556866
CID439492
CID445643
CID5372
CID5472317
CID6426916
CID6436007
CID6473866
CID6536850
CID6610362
CID6912836
CID9832283
CID9853905
CID9918805
CID9940643
CID9963169
Cilag brand OF tacrolimus
CPD000466356
CPD-10016
D08556
DB00864
DivK1c_001040
FK 506
FK5
Fk-506
FK506
FK-506
FR 900506
FR900506
|
FR-900506
FT-0082660
Fujimycin
Fujisawa brand OF tacrolimus
Graceptor
HMS1362O21
HMS1792O21
HMS1990O21
HMS2051C18
HMS2093M19
HMS503O21
IDI1_001040
IDI1_002225
Janssen brand OF tacrolimus
K506
KBio1_001040
KBio2_000619
KBio2_003187
KBio2_005755
KBio3_001097
KBio3_001098
KBioGR_000619
KBioSS_000619
L 679934
L-679934
LCP-Tacro
LMPK04000003
LS-64247
MLS000759471
MLS001424054
Modigraf
MolPort-003-666-518
NCGC00163470-01
NCGC00163470-02
NCGC00163470-03
NCGC00163470-04
NCGC00179232-01
NChemBio.2007.16-comp1
nchembio.2007.23-comp2
NINDS_001040
NSC717865
Prograf
Prograf (TN)
Prograft
Protopic
Protopy
S5003_Selleck
SAM001246677
SMR000466356
Tacarolimus
tacrolimus
Tacrolimus
Tacrolimus (anhydrous)
Tacrolimus (INN)
Tacrolimus (Prograf?)
Tacrolimus anhydrous
tacrolimus hydrate
Tacrolimus, anhydrous
Tsukubaenolide
UNII-Y5L2157C4J
|
|
9 |
|
Ritonavir |
Approved, Investigational |
Phase 4 |
|
155213-67-5 |
392622 |
Synonyms:
1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate
155213-67-5
1hxw
1sh9
538, ABT
5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S)-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate
5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate
A-84538
Abbott 84538
ABBOTT-84538
ABT 538
ABT 84538
ABT538
ABT-538
AC1L94GB
AC-733
AKOS000280930
BIDD:GT0387
BIDD:PXR0023
Bio-0093
C07240
C37H48N6O5S2
CHEBI:45409
CHEMBL163
CID392622
CPD000466395
D00427
D019438
DB00503
|
DRG-0244
FT-0082824
HMS2051B08
HSDB 7160
LS-148860
MLS000759541
MLS001424063
MolPort-000-883-877
N-[(2S,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl]-N~2~-(methyl{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}carbamoyl)-L-valinamide
NCGC00159462-02
Norvir
Norvir (TM)
Norvir (TN)
Norvir Sec
NSC693184
RIT
ritonavir
Ritonavir
Ritonavir (JAN/USAN/INN)
Ritonavir [USAN]
Ritonavir is an inhibitor of HIV protease used to treat HIV infection and AIDS.
Ritonavirum
RTV
S1185_Selleck
SAM001246783
SMR000466395
STK634209
ZINC03944422
|
|
10 |
|
Zidovudine |
Approved |
Phase 4 |
|
30516-87-1 |
35370 |
Synonyms:
1-(3-Azido-2,3-dideoxy-beta-D-ribofuranosyl)thymine
3' azido 2',3' Dideoxythymidine
3' Azido 2',3' Dideoxythymidine
3' azido 3' Deoxythymidine
3' Azido 3' deoxythymidine
3&prime
30516-87-1
399024-19-2
3'-azido-2',3'-Dideoxythymidine
3'-Azido-2',3'-Dideoxythymidine
3'-azido-3'-Deoxythymidine
3'-Azido-3'-deoxythymidine
3-Azido-3-deoxythymidine
3'-Azido-3'-deoxythymidine & Concanavalin A
3'-Azido-3'-deoxythymidine & Erythropoietin
3'-Azido-3'-deoxythymidine & Heteropolyoxotungstate PM-19
3'-Azido-3'deoxythymidine & Interferon .alpha.
3'-Azido-3'-deoxythymidine & Interleukin-1
3'-Azido-3'-deoxythymidine & Interleukin-2
3'-Azido-3'-deoxythymidine & Interleukin-6
3'-Azido-3'-deoxythymidine & Lithium & Erythropoietin
3'-Azido-3'-deoxythymidine & Lithium & Interleukin-1
3'-Azido-3'-deoxythymidine & Lithium & Interleukin-6
3'-Azido-3'-deoxythymidine & Lymphoblastoid Interferon
3'-Azido-3'-deoxythymidine & Sho-Saiko-To
3'-Azido-3'-deoxythymidine (AIDS)
3'-azido-3'-deoxythymidine, AZT
3'-Azidothymidine
3'-Deoxy-3'-azidothymidine
A2169_SIGMA
AC1L1TKL
AC1Q2OEK
antiviral
Antiviral azt
Antiviral AZT
Apo-Zidovudine
-Azido-3&prime
azidodeoxythymidine
Azidothymidine
AZT
AZT & CD4(178)-PE 40
AZT & Colony-stimulating factor 2
AZT & Concanavalin A (ConA)
AZT & EPO
AZT & GM-CSF
AZT & HPA
AZT & IFN.alpha.
AZT & IL-1
AZT & IL-2
AZT & IL-6
AZT & Interferon-.alpha.-2
AZT & Li & EPO
AZT & Li & GM-CSF
AZT & Li & IL-1
AZT & Li & IL-6
AZT & Lymphoblastoid Interferon
AZT & NP (from PHCA or HSA)
AZT & PM-19
AZT & rIFN.alpha.2
AZT & rsCD4 & rIFN.alpha.A
AZT & rsT4
AZT & sCD4
AZT & srCD4
AZT & SST
AZT (antiviral)
AZT (Antiviral)
AZT antiviral
AZT Antiviral
AZT TRANSPLACENTAL CARCINOGENESIS STUDY
AZT, antiviral
AZT, Antiviral
AZT+PRO 140
Aztec
BB_NC-1012
BPBio1_000403
BRD-K72903603-001-04-6
BSPBio_000365
BSPBio_003153
BW a509U
BW A509U
BWA 509u
BWA 509U
BW-A 509U
BWA509u
BWA-509u
BWA509U
BWA-509U
BW-A509U
BW-A-509U
C07210
|
CCRIS 105
CHEBI:10110
CHEBI:127307
CHEMBL129
CID35370
Compound S
Cpd S
CPD000058351
D00413
D015215
DB00495
-deoxythymidine
DivK1c_000524
DRG-0004
DS-4152 & AZT
HMS1921J20
HMS2090G11
HMS2092D06
HMS501K06
HSDB 6515
IDI1_000524
Interferon AD + 3'-azido-3'-deoxythymidine
Intron A & AZT
K7 [P Ti2 W10 O40]
KBio1_000524
KBio2_001828
KBio2_004396
KBio2_006964
KBio3_002653
KBioGR_000703
KBioSS_001828
Liposomal AZT-SN-1
Liposomal AZT-SN-3
LS-1159
Met-SDF-1.beta. & AZT
Met-SDF-1.beta. & Zidovudine
MLS000028548
MLS001055351
MLS001076358
MLS002153202
MLS002222249
MolPort-002-507-286
NCGC00023945-03
NCGC00023945-04
NCGC00023945-05
NCGC00023945-08
NCGC00178237-01
NCGC00178237-02
NINDS_000524
Novo-Azt
NSC 602670
PC-SOD+AZT
Prestwick3_000333
Propolis+AZT
Racemic Liposomal AZT
racemic-dipalmitoylglycerophospho-AZT (in a lipid vesicle)
Retrovir
Retrovir (TN)
Retrovir(TM)
rIFN-beta seron & AZT
SAM002548971
SMR000058351
SN-1-dipalmitoylglycerophospho-AZT (in a lipid vesicle)
SN-3-dipalmitoylglycerophospho-AZT (in a lipid vesicle)
SPBio_000834
Spectrum_001348
SPECTRUM1502109
Spectrum2_000927
Spectrum3_001507
Spectrum4_000332
Spectrum5_001101
STK801891
UNII-4B9XT59T7S
ZDV
zidovudin
Zidovudin
Zidovudina
Zidovudina [Spanish]
zidovudine
Zidovudine
Zidovudine (JAN/USP/INN)
ZIDOVUDINE [AZT]
Zidovudine [USAN:INN:BAN:JAN]
Zidovudine EP III
Zidovudine+PRO 140
Zidovudinum
Zidovudinum [Latin]
ZINC03779042
ZVD
|
|
11 |
|
Lopinavir |
Approved |
Phase 4 |
|
192725-17-0 |
92727 |
Synonyms:
(1S-(1R*(R*),3R*,4R*))-N-(4-(((2,6-Dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pyrimidineacetamide
(2S)-N-[(2S,4S,5S)-5-[[2-(2,6-dimethylphenoxy)acetyl]amino]-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide
(alphaS)-Tetrahydro-N-((alphaS)-alpha-((2S,3S)-2-hydroxy-4-phenyl-3-(2-(2,6-xylyloxy)acetamido)butyl)phenethyl)-alpha-isopropyl-2-oxo-1(2H)-pyrimidineacetamide
1(2H)-Pyrimidineacetamide, N-[(1S,3S,4S)-4-[[(2,6-dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro-alpha-(1-methylethyl)-2-oxo-, (alphaS)- (9CI)
192725-17-0
1mui
2o4s
2q5k
2rkf
2rkg
378, ABT
A 157378
A 157378.0
A-157378.0
A-157378-0
AB1
ABT 157378
ABT 378
ABT-378
ABT-378, LOPINAVIR
ABT-378a-157378-0a-157378.0
AC1L3OPJ
AIDS032937
Aluviran
|
C12871
C37H48N4O5
CHEBI:40456
CHEMBL729
CID92727
D01425
DB01601
Kaletra
Koletra
Lopinavir
Lopinavir (JAN/USAN/INN)
Lopinavir [USAN:INN:BAN]
LPV
LS-173766
MolPort-003-848-410
N-(4-(((2,6-dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pydrimidineacetamide
N-(4-(((2,6-Dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pydrimidineacetamide
N-{1-BENZYL-4-[2-(2,6-DIMETHYL-PHENOXY)-ACETYLAMINO]-3-HYDROXY-5-PHENYL-PENTYL}-3-METHYL-2-(2-OXO-TETRAHYDRO-PYRIMIDIN-1-YL)-BUTYRAMIDE
NCGC00164576-01
NCGC00164576-02
RS-346
S1380_Selleck
UNII-2494G1JF75
|
|
12 |
|
Pioglitazone |
Approved, Investigational |
Phase 4 |
|
111025-46-8 |
4829 |
Synonyms:
(+-)-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
(+-)-5-((4-(2-(5-Ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
(+/-)-5-[[4-[2-(5-Ethyl-2-pyridinyl)-ethoxy]phenyl]methyl]-2,4-thiazolidinedione
(+/-)-5-[p-[2-(ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione
(±)-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
105355-27-9
111025-46-8
198077-89-3
2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]- (9CI)
5-((4-(2-(5-Ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
5-(4-(2-(5-ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione
5-(4-(2-(5-Ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione
5-[[4-[2-(5-Ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione
5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]thiazolidine-2,4-dione
5-[[4-[2-[(5-ethyl-2-pyridyl)]ethoxy]phenyl]methyl]thiazolidine- 2,4-dione
5-[4-[2-(5-Ethyl-2-pyridyl)ethoxy]benzyl]thiazolidine-2,4-dione
5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-1,3-thiazolidine-2,4-dione
AB1004597
AC-1021
AC1L1J1Q
Actos
Actos (TN)
Actost
AD 4833
AD-4833
BRD-A48430263-003-02-4
BSPBio_002723
C07675
C19H20N2O3S
CHEBI:8228
CHEMBL595
CID4829
D08378
DB01132
Duetact
Glustin
HMS2089H14
HS-0047
|
HSDB 7322
I06-0089
KBio2_002103
KBio2_004671
KBio2_007239
KBio3_001943
KBioGR_001619
KBioSS_002103
LS-151327
MolPort-002-508-211
NCGC00163128-01
NCGC00163128-02
nchembio790-comp10
Pioglitazona
Pioglitazona [INN-Spanish]
Pioglitazone
pioglitazone (INN)
Pioglitazone [Ban:Inn]
Pioglitazone [BAN:INN]
Pioglitazone [INN:BAN]
pioglitazone HCl
Pioglitazone HCL
Pioglitazone hydrochloride
Pioglitazone Hydrochloride
Pioglitazonum
Pioglitazonum [INN-Latin]
SPBio_001897
Spectrum_001623
Spectrum2_001679
Spectrum3_001002
Spectrum4_001130
Spectrum5_001480
Spectrum5_002067
U 72107
U 72107A
U72,107A
U-72107
UNII-X4OV71U42S
Zactos
|
|
13 |
|
Entecavir |
Approved, Investigational |
Phase 4 |
|
142217-69-4 |
153941 |
Synonyms:
142217-69-4
209216-23-9
2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one
2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-1,9-dihydro-6H-purin-6-one
2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-1,9-dihydro-6H-purin-6-one--water (1/1)
2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-3H-purin-6-one
6-H-Purin-6-one-,2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]
9-((1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl)guanine monohydrate
AB1004838
AC-1593
AC1L4BEC
Anhydrous entecavir
Baraclude
Baraclude (TN)
BMS-200475
CHEBI:473990
CHEBI:59902
CHEMBL713
CID153941
D04008
|
D07896
DB00442
Entecavir
Entecavir (anhydrous)
Entecavir (INN)
Entecavir (USAN)
Entecavir anhydrous
Entecavir hydrate
Entecavir hydrate (JAN)
entecavir monohydrate
Entecavirum
ETV
FT-0083013
MolPort-005-942-963
S2128_Selleck
SBB066120
SQ-34676
TL8000933
ZINC03802690
|
|
14 |
|
Lactulose |
Approved |
Phase 4 |
|
4618-18-2 |
11333 |
Synonyms:
(2S,3R,4S,5R,6R)-2-[(2R,3S,4S,5R)-4,5-Dihydroxy-2,5-bis(hydroxymethyl)oxolan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
4-O-b-D-Galactopyranosyl-D-fructofuranose
4-O-b-D-Galactopyranosyl-D-fructose
4-O-beta-delta-Galactopyranosyl-delta-fructofuranose
4-O-beta-delta-Galactopyranosyl-delta-fructose
4-O-beta-D-Galactopyranosyl-D-fructofuranose
4-O-beta-D-Galactopyranosyl-D-fructose
4-O-β-D-galactopyranosyl-D-fructofuranose
4-O-β-D-galactopyranosyl-D-fructose
Amivalex
|
Bifiteral
Cephulac
delta-Lactulose
D-Lactulose
Duphalac
Lactulosa
Lactulose
Lactulosum
Normase
|
|
15 |
|
Methadone |
Approved |
Phase 4 |
|
76-99-3 |
4095 |
Synonyms:
(-)-(R)-6-(Dimethylamino)-4,4-diphenyl-3-heptanone
(-)-Methadone
(+)-Methadone
(+-)-Methadone
(+/-)-methadone
(+/-)-Methadone
(+/-)-methadone hydrochloride
(+/-)-Methadone hydrochloride
(+/-)-Tussal
(±)-methadone
(6R)-Methadone
(R)-6-(Dimethylamino)-4,4-diphenyl-3-heptanone
(R)-6-(Dimethylamino)-4,4-diphenyl-3-hetpanone
(S)-6-(Dimethylamino)-4,4-diphenyl-3-heptanone
1095-90-5 (hydrochloride)
297-88-1
3-14-00-00278 (Beilstein Handbook Reference)
3-14-00-00279 (Beilstein Handbook Reference)
3-Hetpanone, 6-(dimethylamino)-4,4-diphenyl-, (R)- (9CI)
5653-80-5
6-(Dimethylamino)-4,4-diphenyl-3-heptanone dl-mixture
6-(dimethylamino)-4,4-diphenylheptan-3-one
6-dimethylamino-4,4-di(phenyl)heptan-3-one
6-dimethylamino-4,4-Diphenyl-3-heptanone
6-Dimethylamino-4,4-diphenyl-3-heptanone
6S-Methadone
76-99-3
A 4624
AC-16055
AC1L1HEG
AC1Q2RLW
Adanon
Adanon hydrochloride
AddiCare brand OF methadone hydrochloride
Adolan
Algidon
Algolysin
Algovetin
Althose
Althose hydrochloride
Amidon
Amidone
AN 148
AN-148 (*Hydrochloride*)
Biodone
Biomet brand OF methadone hydrochloride
Biscuits
BRN 3213667
BRN 3213668
BRN 3213669
Butalgin
C07163
CHEBI:6807
CHEMBL651
CID4095
D08195
d-6-(Dimethylamino)-4,4-diphenyl-3-heptanone
DB00333
DEA No. 9250
Depridol
Dextromethadone
Diaminon
Diaminon hydrochloride
DivK1c_000963
dl-Methadone
DL-Methadone
DL-Methadone hydrochloride
d-Methadone
Dollies
Dolly
Dolofin hydrochloride
Dolohepton
Dolophin
Dolophin hydrochloride
Dolophine
Dolophine (*Hydrochloride*)
Dolophine HCL
EINECS 200-996-9
Esteve brand OF methadone hydrochloride
Fenadon
Fenadone
Fenadone (*Hydrochloride*)
Generics brand OF methadone hydrochloride
GlaxoSmithKline brand OF methadone hydrochloride
|
Heptadon
Heptadone
Heptadone (*Hydrochloride*)
Heptanon
Heptanon (*Hydrochloride*)
Heptanon (pharmaceutical)
Hoechst 10820
Hoescht 10820 (*Hydrochloride*)
HSDB 3119
Hydrochloride, methadone
IDI1_000963
K 174
KBio1_000963
Ketalgin
Ketalgin hydrochloride
L-(+)-Methadone
L000874
L-6-(Dimethylamino)-4,4-diphenyl-3-heptanone
Levometadona
Levometadona [INN-Spanish]
Levomethadone [INN]
Levomethadonum
Levomethadonum [INN-Latin]
Levothyl
l-Methadone
L-Polamidon
l-Polamivet
LS-74485
LS-74486
LS-74487
Mallinckrodt brand OF methadone hydrochloride
Martindale brand OF methadone hydrochloride
Mecodin
Mephenon
Metadol
Metadona
Metadona [INN-Spanish]
Metadona [Spanish]
Metadone
Metadone [DCIT]
Metasedin
Methaddict
Methadon
Methadona
Methadona [Spanish]
methadone
Methadone
Methadone (BAN)
Methadone [INN:BAN]
Methadone HCL
Methadone HCL Intensol
Methadone hydrochloride
Methadone M
Methadonum
Methadonum [INN-Latin]
Methadonum [Latin]
Methadose
Methaquaione
Methex
Miadone
Moheptan
MolPort-001-785-650
NINDS_000963
Pharmascience brand OF methadone hydrochloride
Phenadone
Phenadone (*Hydrochloride*)
Phenadone hydrochloride
Phymet
Physeptone
Pinadone
Pinewood brand OF methadone hydrochloride
Polamidon
Polamidone
Polamivet
Racemic methadone
Rosemont brand OF methadone hydrochloride
Roxane brand OF methadone hydrochloride
S-(+)-Methadone
Sedo-Rapide
Symoron
Tussol
UNII-UC6VBE7V1Z
Westadone
Yamanouchi brand OF methadone hydrochloride
|
|
16 |
|
Velpatasvir |
Approved, Investigational |
Phase 4 |
|
1377049-84-7 |
67683363 |
Synonyms:
|
17 |
|
Emtricitabine |
Approved, Investigational |
Phase 4 |
|
143491-57-0 |
60877 |
Synonyms:
(-)-(2R,5S)-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
(−)-(2R,5S)-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
(-)-(2R,5S)-5-fluoro-1-[2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
(-)-.beta.-L-FTC
(-)-2',3'-Dideoxy-5-fluoro-3'-thiacytidine
(−)-2'-deoxy-5-fluoro-3'-thiacytidine
(-)-2'-Deoxy-5-fluoro-3'-thiacytidine
(-)-b-2',3'-Dideoxy-5-fluoro-3'-thiacytidine
(-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine
(-)-beta-2',3'-Dideoxy-5-fluoro-3'-thiacytidine
(-)-cis-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one
(−)-cis-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one
(-)-cis-4-amino-5-fluoro-1-(2-Hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one
(-)-FTC
(−)-FTC
(-)-β-2',3'-dideoxy-5-fluoro-3'-thiacytidine
(−)-β-2',3'-dideoxy-5-fluoro-3'-thiacytidine
(2R-cis)-4-amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone
(2R-cis)-4-amino-5-fluoro-1-(2-(Hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone
(2R-cis)-4-Amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone
.beta.-L-(-)-(2R,5S)-5-Fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
1-(2-(Hydroxymethyl)oxathiolan-5-yl)-5-fluorocytosine
143491-54-7
143491-57-0
145213-48-5
2',3',5-FTC
2',3'-Dideoxy-5-fluoro-3'-thiacytidine
2'-Deoxy-5-fluoro-3'-oxa-4'-thiocytidine
2'-Deoxy-5-fluoro-3'-thiacytidine
2-FTC
3'-Thia-2'.3'-dideoxy-5-fluorocytidine
4-amino-5-fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one
4-amino-5-fluoro-1-((2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one
4-amino-5-fluoro-1-((2R,5S)-2-Hydroxymethyl-[1,3]oxathiolan-5-yl)-1H-pyrimidin-2-one
4-Amino-5-fluoro-1-((2R,5S)-2-hydroxymethyl-[1,3]oxathiolan-5-yl)-1H-pyrimidin-2-one
4-Amino-5-fluoro-1-[(2R,5S)-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone
4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one
4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one
524W91
5-fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine
5-fluoro-1-((2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine
5-Fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine
|
5-Fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine
5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)[1,3]oxathiolan-5-yl]cytosine
AC1L1U3I
AC1Q4KUB
beta-L-2',3'-dideoxy-5-fluoro-3'-thiacytidine
BW 1592
BW 524W91
BW524W91
BW-524W91
C122114
C12599
C8H10FN3O3S
CHEBI:31536
CHEMBL885
CID60877
Coviracil
Coviracil(TM)
D01199
DB00879
dOTFC
DRG-0208
Emtricitabin
Emtricitabina
Emtricitabine
Emtricitabine (JAN/USAN/INN)
Emtricitabinum
Emtriva
Emtriva (TN)
Emtriva(TM)
FT-0080009
HMS2089I05
HSDB 7337
LS-135838
LS-173184
NCGC00164564-01
Racivir
RCV
SBB066061
TL8000958
UNII-G70B4ETF4S
ZINC03629271
|
|
18 |
|
Naloxone |
Approved, Vet_approved |
Phase 4 |
|
465-65-6 |
5284596 |
Synonyms:
(-)-N-allyl-14-hydroxynordihydroxymorphinan-6-one
(−)-naloxone
(-)-Naloxone
(5alpha)-3,14-dihydroxy-17-prop-2-en-1-yl-4,5-epoxymorphinan-6-one
(5alpha)-4,5-Epoxy-3,14-dihydroxy-17-(2-propenyl)morphinan-6-one
12-Allyl-7,7a,8,9-tetrahydro-3,7a-dihydroxy-4aH-8,9c-iminoethanophenanthro(4,5-bcd)furanone
12-Allyl-7,7a,8,9-tetrahydro-3,7a-dihydroxy-4aH-8,9c-iminoethanophenanthro[4,5-bcd]furan-5(6H)-one
17-Allyl-3,14-dihydroxy-4,5a-epoxymorphinan-6-one
17-allyl-3,14-dihydroxy-4,5alpha-epoxymorphinan-6-one
17-Allyl-3,14-dihydroxy-4,5alpha-epoxymorphinan-6-one
17-allyl-3,14-dihydroxy-4,5α-epoxymorphinan-6-one
17-Allyl-3,14-dihydroxy-4,5α-epoxymorphinan-6-one
17-Allyl-4,5alpha-epoxy-3,14-dihydroxymorphinan-6-one
17-Allyl-4,5-alpha-epoxy-3,14-dihydroxymorphinan-6-one
1-N-Allyl-14-hydroxynordihydromorphinone
1-N-Allyl-7,8-dihydro-14-hydroxynormorphinone
3,14-dihydroxy-17-(prop-2-en-1-yl)-4,5alpha-epoxymorphinan-6-one
357-08-4 (hydrochloride)
465-65-6
abello Brand OF naloxone hydrochloride
abello, Naloxone
BIDD:GT0110
Boots brand OF naloxone hydrochloride
BPBio1_000136
BRD-K67511046-003-03-7
Bristol myers squibb brand OF naloxone hydrochloride
Bristol-myers squibb brand OF naloxone hydrochloride
BRN 1089071
BSPBio_000122
C07252
CHEBI:7459
CHEMBL80
CID5284596
Curamed brand OF naloxone hydrochloride
Curamed, naloxon
D08249
DB01183
DBL Naloxone
DBL Naloxone (TN)
Dihydride, naloxone hydrochloride
EINECS 207-365-7
EN 1530 base
EN 1530 Base
endo Brand OF naloxone hydrochloride
HMS2090F20
HSDB 3279
Hydrobromide, naloxone
Hydrochloride dihydride, naloxone
Hydrochloride, naloxone
lamepro Brand OF naloxone hydrochloride
l-N-Allyl-14-hydroxynordihydromorphinone
l-N-Allyl-7,8-dihydro-14-hydroxynormorphinone
l-Naloxone
L-Naloxone
|
LS-187184
LS-92141
MolPort-002-536-640
Morphinan-6-one, 17-allyl-4,5alpha-epoxy-3,14-dihydroxy- (8CI)
Morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-17-(2-propenyl)-, (5alpha)- (9CI)
MRZ 2593 BR
MRZ 2593BR
MRZ 2593-BR
N-Allyl-4,5alpha-epoxy-3,14-dihydroxy-6-morphinanon
n-Allylnoroxymorphone
N-Allylnoroxymorphone
N-Allyl-noroxymorphone
Nalone
Nalossone
Nalossone [Dcit]
Nalossone [DCIT]
Naloxon curamed
Naloxon ratiopharm
Naloxona
Naloxona [INN-Spanish]
naloxone
Naloxone
Naloxone (INN)
Naloxone [INN:BAN]
Naloxone abello
Naloxone HCl
Naloxone hydrobromide
Naloxone hydrochloride
Naloxone hydrochloride dihydride
Naloxone hydrochloride, (5 beta,9 alpha,13 alpha,14 alpha)-isomer
Naloxone, (5 beta,9 alpha,13 alpha,14 alpha)-isomer
Naloxonratiopharm
Naloxon-ratiopharm
Naloxonum
Naloxonum [INN-Latin]
Narcan
Narcanti
Narcon
NCGC00024674-02
NSC 70413
NSC70413
PDSP2_001520
Prestwick0_000111
Prestwick1_000111
Prestwick2_000111
Prestwick3_000111
Ratiopharm brand OF naloxone hydrochloride
SERB brand OF naloxone hydrochloride
SMP1_000205
SPBio_002061
STOCK1N-69923
UNII-36B82AMQ7N
United drug brand OF naloxone hydrochloride
|
|
19 |
|
Buprenorphine |
Approved, Illicit, Investigational, Vet_approved |
Phase 4 |
|
52485-79-7 |
40400 644073 |
Synonyms:
(-)-buprenorphine
(−)-buprenorphine
(-)-Buprenorphine
(5alpha,6beta,14beta,18R)-17-(cyclopropylmethyl)-18-[(1S)-1-hydroxy-1,2,2-trimethylpropyl]-6-(methyloxy)-18,19-dihydro-4,5-epoxy-6,14-ethenomorphinan-3-ol
(5alpha,6beta,14beta,18R)-17-(cyclopropylmethyl)-18-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-6-methoxy-18,19-dihydro-4,5-epoxy-6,14-ethenomorphinan-3-ol
[5alpha,7alpha(S)]-17-(Cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-6,14-ethenomorphinan-7-methanol
17-Cyclopropylmethyl-4,5a-epoxy-7a-((S)-1-hydroxy-1,2,2-trimethylpropyl)-6-methoxy-6,14-endo-ethanomorphinan-3-ol
17-cyclopropylmethyl-4,5alpha-epoxy-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl)-6-methoxy-6,14-endo-ethanomorphinan-3-ol
17-Cyclopropylmethyl-4,5alpha-epoxy-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl)-6-methoxy-6,14-endo-ethanomorphinan-3-ol
17-Cyclopropylmethyl-4,5alpha-epoxy-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl-6-methoxy-6,14-endo-ethanomorphinan-3-ol
17-cyclopropylmethyl-4,5α-epoxy-7α-((S)-1-hydroxy-1,2,2-trimethylpropyl)-6-methoxy-6,14-endo-ethanomorphinan-3-ol
17-Cyclopropylmethyl-4,5α-epoxy-7α-((S)-1-hydroxy-1,2,2-trimethylpropyl)-6-methoxy-6,14-endo-ethanomorphinan-3-ol
2-(N-Cyclopropylmethyl-4,5a-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-6a-yl)-3,3-dimethyl-2-butanol
2-(N-cyclopropylmethyl-4,5alpha-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-6alpha-yl)-3,3-dimethyl-2-butanol
2-(N-Cyclopropylmethyl-4,5alpha-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-6alpha-yl)-3,3-dimethyl-2-butanol
2-(N-Cyclopropylmethyl-4,5alpha-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-7alpha-yl)-3,3-dimethyl-2-butanol
2-(N-cyclopropylmethyl-4,5α-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-6α-yl)-3,3-dimethyl-2-butanol
2-(N-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-6α-yl)-3,3-dimethyl-2-butanol
2-[3-cyclopropylmethyl-11-hydroxy-15-methoxy-(14R)-13-oxa-3-azahexacyclo[13.2.2.12,8.01,6.06,14.07,12]icosa-7,9,11-trien-16-yl]-3,3-dimethyl-2-butanol
2-[3-Cyclopropylmethyl-11-hydroxy-15-methoxy-(14R)-13-oxa-3-azahexacyclo[13.2.2.12,8.01,6.06,14.07,12]icosa-7,9,11-trien-16-yl]-3,3-dimethyl-2-butanol
21-(Cyclopropyl-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine
21-Cyclopropyl-7a-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine
21-cyclopropyl-7alpha-(2-hydroxy-3,3-dimethyl-2-butyl)-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine
21-cyclopropyl-7alpha-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine
21-Cyclopropyl-7alpha-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine
21-cyclopropyl-7α-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine
21-Cyclopropyl-7α-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine
52485-79-7
53152-21-9 (hydrochloride)
6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-,
6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-, (alphaS,5alpha,7alpha)- (9CI)
6029-M
AC1L23NL
AC1L9B1M
AC1LD8IH
Buprel
Buprenex
Buprenophine
Buprenorfina
Buprenorfina [INN-Spanish]
buprenorphine
Buprenorphine
Buprenorphine (JAN/INN)
Buprenorphine [INN:BAN]
Buprenorphine grünenthal brand
|
Buprenorphine Hcl
Buprenorphine hydrochloride
Buprenorphinum
Buprenorphinum [INN-Latin]
Buprex
C08007
C29H41NO4
CHEBI:3216
CHEMBL1201894
CHEMBL47085
CID40400
CID441363
CID5311033
CID6321408
CID644073
D07132
DB00921
DEA No. 9064
EINECS 257-950-6
Essex brand OF buprenorphine hydrochloride
Grünenthal brand OF buprenorphine
Grünenthal brand OF buprenorphine hydrochloride
Hydrochloride, buprenorphine
Key brand OF buprenorphine hydrochloride
LS-67682
MolPort-004-285-844
PDSP2_000111
Prefin
Probuphine
Reckitt and colman brand 1 OF buprenorphine hydrochloride
Reckitt and colman brand 2 OF buprenorphine hydrochloride
Reckitt benckiser brand OF buprenorphine hydrochloride
Reckitt brand OF buprenorphine hydrochloride
RX 6029 m
RX 6029M
RX-6029-m
RX-6029-M
Schering plough brand OF buprenorphine hydrochloride
Schering-plough brand OF buprenorphine hydrochloride
Subutex
Temgesic
Temgésic
Temgesic (TN)
UNII-40D3SCR4GZ
|
|
20 |
|
Cobicistat |
Approved |
Phase 4 |
|
1004316-88-4 |
|
Synonyms:
1,3-thiazol-5-ylmethyl [(2R,5R)-5-{[(2S)-2-({[(2-isopropyl-1,3-thiazol-4-yl)methyl](methyl)carbamoyl}amino)-4-(morpholin-4-yl)butanoyl]amino}-1,6-diphenylhexan-2-yl]carbamate
|
|
|
21 |
|
Ribavirin |
Approved |
Phase 4 |
|
36791-04-5 |
37542 |
Synonyms:
1-.beta.-D-Ribofuranosyl-1,2,4-triazolo-3-carboxamide
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-1,2,4-triazole-3-carboxamide
1-b-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide
1-b-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide
1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide
1-beta-D-ribofuranosyl-1-H-1,2,4-triazole-3-carboxamide
1-beta-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide
1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
1-β-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide
36791-04-5
437710-49-1
66510-90-5
AA-504/07617051
AB00430481
AC1L1XXZ
AC1Q1IDC
AC1Q4ZGS
AKOS001715163
BB_NC-0567
BPBio1_001195
BRN 0892462
BSPBio_001085
BSPBio_003352
CHEMBL1643
CID37542
Copegus
Copegus (TN)
Cotronak
C-Virin
D00423
DB00811
Dermatech brand OF ribavirin
DivK1c_000782
DRG-0028
Drug: Ribavirin
Essex brand OF ribavirin
EU-0101063
FT-0082885
Grossman brand OF ribavirin
HMS2090L15
HMS2094O09
HMS502H04
HSDB 6513
ICN brand OF ribavirin
ICN-1229
IDI1_000782
KBio1_000782
KBio2_002328
KBio2_004896
KBio2_007464
KBio3_002854
KBioGR_001804
KBioSS_002331
KS-1104
Lopac0_001063
LS-1241
Merck brand OF ribavirin
MLS000028486
MLS002222317
MolPort-002-507-104
MolPort-002-885-856
NCGC00090726-01
NCGC00090726-03
NCGC00090726-04
NCGC00090726-05
NCGC00090726-06
NCGC00090726-07
|
NINDS_000782
NSC 163039
NSC163039
Pfizer brand OF ribavirin
Prestwick3_000993
R 9644
R-964
R9644_SIGMA
Ravanex
RBV
Rebetol
Rebetol (TN)
Rebetron
Rebretron
RG-964
Ribacine
Ribamide
Ribamidil
Ribamidyl
Ribasphere
Ribasphere (TN)
Ribav
RIBAV
ribavirin
Ribavirin
Ribavirin (JAN/USP/INN)
Ribavirin [USAN:INN]
Ribavirin Capsules
Ribavirin merck brand
Ribavirin Triphosphate
Ribavirina
Ribavirina [INN-Spanish]
Ribavirine
Ribavirine [INN-French]
Ribavirin-TP
Ribavirinum
Ribavirinum [INN-Latin]
Ribovirin
Ro 20-9963/000
Ro-20-9963
RTC
RTCA
RTP
S2504_Selleck
SCH 18908
SMP1_000261
SMR000058315
Spectrum_001826
SPECTRUM1503938
Spectrum3_001876
Spectrum4_001252
Spectrum5_002075
SR-01000076112-3
Three rivers pharmaceuticals brand OF ribavirin
Tribavirin
UNII-49717AWG6K
Varazid
Vilona
Viramid
Viramide
Virazid
Virazide
Virazole
Virazole (Ribavirin) Inhalation Solution
Virazole (TN)
Virazole 5'-triphosphate
ZINC01035331
|
|
22 |
|
Nevirapine |
Approved |
Phase 4 |
|
129618-40-2 |
4463 |
Synonyms:
11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one
11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one & PRO 140 (Anti-CCR5 monoclonal antibody)
11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one
11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one
11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one
11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-6H-DIPYRIDO[3,2-B:2',3'-E][1,4]DIAZEPIN-6-ONE
129618-40-2
1vrt
2hny
AC1L1I81
AC-643
BI RG 587
BIDD:GT0326
Bio-0789
BIRG 0587
BIRG 587
BIRG-0587
BIRG587
BIRG-587
BI-RG-587
BI-RG-587 & CD4-IgG
C07263
C15H14N4O
Cahill May Roberts Brand of Nevirapine
CHEBI:44659
CHEMBL57
CID4463
CPD000048458
D00435
D019829
DB00238
DB08311
Hemihydrate, nevirapine
HMS2051J09
HSDB 7164
|
I02-0310
LS-2289
MLS000084585
MLS000759409
MLS001055309
MLS001201730
MolPort-002-507-817
N11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e]-[1,4]diazepin-6-one & CD4-immunoadhesin
NCGC00065890-02
NEV
Nevirapina
nevirapine
Nevirapine
Nevirapine & CD4-IgG
Nevirapine & PRO 140
Nevirapine (JAN/USP/INN)
Nevirapine [USAN:INN]
Nevirapine anhydrous
Nevirapine hemihydrate
Nevirapine, anhydrous
NON-NUCLEOSIDE RT INHIBITOR NEVIRAPINE
NSC 641530
NSC641530
NVP
Promeco Brand of Nevirapine
S1742_Selleck
SAM001246551
SMR000048458
STK580320
UNII-99DK7FVK1H
Viramune
Viramune (TN)
Viramune(TM)
Viramune, BI-RG 587, Nevirapine
ZINC00004778
|
|
23 |
|
Efavirenz |
Approved, Investigational |
Phase 4 |
|
154598-52-4 |
64139 |
Synonyms:
(-)-6-chloro-4-CYCLOPROPYLETHYNYL-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one
(-)-Efavirenz
(4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1H-3,1-benzoxazin-2-one
(4S)-6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one
(4S)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one
(4S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
(S)-6-Chloro-4-(2-cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-ben
(S)-6-chloro-4-(Cyclopropylethynyl)-1,4-dihydro-(S)-6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one
(S)-6-chloro-4-(Cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one
(S)-6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one
(S)-6-chloro-4-Cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one
(S)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
(S)-6-chloro-4-Cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[D][1,3]oxazin-2-one
(S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
154598-52-4
1ikv
1ikw
2H-3,1-Benzoxazin-2-one, 6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-, (4S)- (9
6-chloro-4-(2-cyclopropyl-1-ethynyl)-4-trifluoromethyl-(4S)-1,4-dihydro-2H-benzo[d][1,3]oxazin-2-one
6-chloro-4-(2-Cyclopropyl-1-ethynyl)-4-trifluoromethyl-(4S)-1,4-dihydro-2H-benzo[D][1,3]oxazin-2-one
AC-19049
AC1L20IX
BIDD:GT0383
Bristol-myers squibb brand OF efavirenz
C08088
C14H9ClF3NO2
CHEBI:119486
CHEMBL223228
CID64139
CPD000466351
D00896
DB00625
DB07709
DMP 266
DMP-266
Du pont brand OF efavirenz
efavirenz
Efavirenz
|
Éfavirenz
Efavirenz (JAN/INN)
Efavirenz, (R)-isomer
efavirenz, (S)-isomer
Efavirenz, (S)-isomer
Efavirenzum
EFV
EFZ
Eravirenz
HMS2051J08
HMS2090N16
HSDB 7163
L 743726
L-741211
L-743,726
L-743725
L-743726
LS-173464
Merck sharp and dohme brand OF efavirenz
Met-SDF-1.beta. & Efavirenz
Met-Stromal Cell-derived Factor-1.beta. (Human) & Efavirenz
MLS000759465
MLS001424087
MolPort-003-983-924
NSC742403
SAM001246667
SBB066062
SMR000466351
Stocrin
Strocin (TM)
Sustiva
Sustiva (TM)
Sustiva (TN)
UNII-JE6H2O27P8
United drug brand OF efavirenz
ZINC02020233
zoxazin-2-one
|
|
24 |
|
Rifaximin |
Approved, Investigational |
Phase 4 |
|
80621-81-4 |
6436173 46783403 |
Synonyms:
(2S,16Z,18E,20S,21S,22R,23R,24R,25S,26S,27S,28E)-5,6,21,23,25 Pentahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-2,7-(epoxypentadeca(1,11,13)trienimino)benzofuro(4,5-e)pyrido(1,2-a)benzimidazole-1,15(2H)-dione, 25-acetate
4-deoxy-4'-methylpyrido(1',2'-1,2)imidazo(5,4C)rifamycin
4-Deoxy-4'-methylpyrido(1',2'-1,2)imidazo(5,4C)rifamycin
4-Deoxy-4'-methylpyrido(1',2'-1,2)imidazo(5,4-c)rifamycin SV
80621-81-4
88747-56-2
AC-19112
alpha-0817185
Bio-0556
BRN 3584528
C43H51N3O11
CHEMBL1617
D02554
DB01220
Fatroximin
Flonorm
L 105
L 105 (Ansamacrolide antibiotic)
L 105SV
Lormyx
LS-178059
LS-64147
Lumenax
MLS000759430
Normix
Redactiv
|
RedActiv
Rifacol
Rifamixin
Rifamycin L 105
Rifamycin L 105SV
Rifaxidin
Rifaximin
Rifaximin (USAN/INN)
Rifaximin [USAN:INN]
Rifaximina
Rifaximina [Spanish]
Rifaximine
Rifaximine [French]
Rifaximinum
Rifaximinum [Latin]
Rifaximinun
Rifaxin
Ritacol
S1790_Selleck
SMR000466324
Spiraxin
UNII-L36O5T016N
Xifaxan
Xifaxan, Rifacol, Fatroximin, Rifaximin
Xifaxsan
Xifaxsan (TN)
|
|
25 |
|
Vitamin D |
Approved, Nutraceutical, Vet_approved |
Phase 4 |
|
1406-16-2 |
|
Synonyms:
|
Vitamin D, unspecified form
|
|
26 |
|
Vitamin D3 |
Approved, Nutraceutical |
Phase 4 |
|
67-97-0 |
5280795 6221 |
Synonyms:
()-Vitamin D3
(+)-vitamin D3
(+)-Vitamin D3
(1S,3Z)-3-[(2E)-2-[(1R,3AR,7as)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidene-cyclohexan-1-ol
(3 beta,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
(3b,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
(3beta,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(3beta,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
(3S,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(3β,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(3Î’,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(5Z,7E)-(3S)-9,10-seco-5,7,10(19)-cholestatrien-3-ol
(5Z,7E)-(3S)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(5Z,7E)-(3S)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
1406-16-2
25(OH)D
47763_SUPELCO
57651-82-8
67-97-0
7-DEHYDROCHOLESTEROL
7-Dehydrocholesterol activated
7-Dehydrocholesterol, Activated
7-Dehydrocholesterol, irradiated
7-Dehydrocholestrol, activated
8024-19-9
8050-67-7
89193_FLUKA
9,10-Seco(5Z,7E)-5,7,10(19)-cholestatrien-3beta-ol
9,10-Seco(5Z,7E)-5,7,10(19)-cholestatrien-3-ol
9,10-Secocholesta-5(Z),7(E),10(19)-trien-3(.beta.)-ol
9,10-Secocholesta-5,7,10(19)-trien-3-beta-ol
AB1002422
AC-11697
AC1L1ECK
AC1L1M23
AC1LU7IZ
AC1NQXLN
AC1NR2UO
AC1NR2UR
AC1NR2UU
AC1NS4AJ
AC1NSHJX
AC1O5EOF
AC1O7GAV
AC1O7GQ3
AC1O8FEU
AC1O8PWJ
AC1OF2GI
AC1OF2GL
AC1OIEW5
AC1OIEWB
ACon1_001997
ACTIVATED
Activated 7-dehydrocholesterol
Arachitol
Bio-0845
bmse000507
BPBio1_000460
BSPBio_000418
BSPBio_002408
C05443
C1357_SIAL
C27H44O
C9756_SIGMA
C9774_SIAL
Calciol
CAS-67-97-0
CC
CCRIS 5813
CCRIS 6286
CHEBI:283119
CHEBI:28940
CHEMBL1042
CHEMBL432780
cholecalciferol
Cholecalciferol
Cholecalciferol (D3)
Cholecalciferol (JP15/USP)
Cholecalciferol [USAN:BAN:JAN]
Cholecalciferol, D3
Cholecalciferols
Cholecalciferolum
CID10000117
CID10045875
CID10340013
CID10883523
CID10894379
CID11014566
CID11025493
CID11058152
CID11463269
CID1548921
CID2735
CID5280795
CID5283710
CID5283711
CID5283712
CID5353527
CID5363362
CID6221
CID6432644
CID6604201
CID6604662
CID6708595
CID6713938
CID6992015
CID6992016
CID7067439
|
CID7067440
CID7251172
CID7251174
CID9821465
Colecalciferol
Colecalciferol (INN)
Colecalciferolo
Colecalciferolo [DCIT]
Colecalciferolum
Colecalciferolum [INN-Latin]
Colecalcipherol
D00188
D3-Vicotrat
D3-Vigantol
DB00169
Delsterol
Delta-D
Delta-D (TN)
Deparal
Dihydrocholesterol
DivK1c_006276
Duphafral D3 1000
Ebivit
EINECS 200-673-2
EINECS 215-797-2
EPA Pesticide Chemical Code 202901
FeraCol
HMS1569E20
HMS2092M12
HSDB 820
I05-0041
Irradiated 7-dehydrocholesterol
KBio1_001220
KBio2_001643
KBio2_004211
KBio2_006779
KBio3_001628
KBioGR_001602
KBioSS_001643
LMST03020001
LMST03020219
LMST03020220
LMST03020221
LS-1570
LS-825
LT00244775
MEGxm0_000458
Micro-dee
MolPort-001-740-051
MolPort-001-785-972
MolPort-003-666-021
MolPort-004-946-964
NCGC00016301-01
NCGC00017328-01
NCGC00091072-01
NCGC00142511-01
NCGC00159331-02
NCGC00159331-04
NCGC00178668-01
NCGC00179565-01
NCGC00179565-02
NEO Dohyfral D3
NSC 375571
NSC375571
NSC-375571
Oleovitamin D3
Prestwick_63
Prestwick0_000429
Prestwick1_000429
Prestwick2_000429
Prestwick3_000429
Provitamine
Provitina
Rampage
Ricketon
SMP1_000068
SPBio_001298
SPBio_002357
SpecPlus_000180
Spectrum_001163
Spectrum2_001369
Spectrum3_000764
Spectrum4_001201
SR-05000001559
SR-05000001559-3
ST057172
TNP00266
Trivitan
UNII-1C6V77QF41
UPCMLD-DP152
UPCMLD-DP152:001
Vi-de-3-hydrosol
Vigorsan
VITAMIN D
Vitamin D 3
vitamin d-3
Vitamin D3
Vitamin D-3
Vitamin D3 emulsifiable
VITAMIN D3 POWDER
VITAMIN_D3
Vitinc Dan-Dee-3
ZINC04474460
ZINC04492874
ZINC04492875
ZINC04492876
ZINC04492878
δ-D
|
|
27 |
|
Adefovir |
Investigational |
Phase 4 |
|
106941-25-7 |
|
Synonyms:
9-(2-(phosphonomethoxy)ethyl)adenine
9-(2-phosphonylmethoxyethyl)adenine
Adefovir
|
|
|
28 |
|
Tenofovir |
Experimental, Investigational |
Phase 4 |
|
147127-20-6 |
464205 |
Synonyms:
(R)-9-(2-Phosphonomethoxypropyl)adenine
(R)-9-(2-Phosphonylmethoxypropyl)adenine
(R)-PMPA
[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethylphosphonic acid
147127-20-6
206184-49-8
9-(2-Phosphonomethoxypropyl)adenine
9-(2-Phosphonylmethoxypropyl)adenine
9-(2-Phosphonylmethoxypropyl)adenine, (+-)-isomer
9-(2-Phosphonylmethoxypropyl)adenine, (R)-isomer - T357098
9-(2-Phosphonylmethoxypropyl)adenine, (S)-isomer
9-PMPA (tenofovir)
AC1LA9BO
AC-760
Anh. tenofovir
Anhydrous tenofovir
Apropovir
CHEBI:45809
CHEMBL483
CID464205
D,L-Tenofovir
DB00300
Disoproxil fumarate, tenofovir
Disoproxil, tenofovir
Fumarate, tenofovir disoproxil
GNA & Tenofovir
|
GS 1275
GS 1278
GS1278
HHA & Tenofovir
KS-5021
MolPort-003-850-411
NCGC00167535-01
Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]- & Galanthus nivalis agglutinin (GNA)
Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]- & Hippeastrum hybrid agglutinin( HHA)
Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]- (9CI)
Phosphonic acid, [[2-(6-amino-9H-purin-9
PMPA
PMPA-(R)
S1401_Selleck
TDF
Tenefovir
Tenofovir
Tenofovir (anh.)
Tenofovir (anhydrous)
Tenofovir anhydrous
Tenofovir disoproxil
Tenofovir disoproxil fumarate
TFV
UNII-99YXE507IL
Viread
Viread, Tenofovir
|
|
29 |
|
Anticholesteremic Agents |
|
Phase 4 |
|
|
|
30 |
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors |
|
Phase 4 |
|
|
|
31 |
|
Interferon alpha-2 |
|
Phase 4 |
|
|
|
32 |
|
interferons |
|
Phase 4 |
|
|
|
33 |
|
Interferon-alpha |
|
Phase 4 |
|
|
|
34 |
|
Vitamins |
|
Phase 4 |
|
|
|
35 |
|
Immunologic Factors |
|
Phase 4 |
|
|
|
36 |
|
Trace Elements |
|
Phase 4 |
|
|
|
37 |
|
Nutrients |
|
Phase 4 |
|
|
|
38 |
|
Micronutrients |
|
Phase 4 |
|
|
|
39 |
|
Calciferol |
|
Phase 4 |
|
|
|
40 |
|
Immunosuppressive Agents |
|
Phase 4 |
|
|
|
41 |
|
Hypoglycemic Agents |
|
Phase 4 |
|
|
|
42 |
|
Dihydroxycholecalciferols |
|
Phase 4 |
|
|
|
43 |
|
Calcium, Dietary |
|
Phase 4 |
|
|
|
44 |
|
Dextrans |
|
Phase 4 |
|
|
|
45 |
|
Anticoagulants |
|
Phase 4 |
|
|
|
46 |
|
Plasma Substitutes |
|
Phase 4 |
|
|
|
47 |
|
Iron-Dextran Complex |
|
Phase 4 |
|
|
|
48 |
|
Blood Substitutes |
|
Phase 4 |
|
|
|
49 |
|
Calcineurin Inhibitors |
|
Phase 4 |
|
|
|
50 |
|
Lamivudine, zidovudine drug combination |
|
Phase 4 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 312)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Effects of Short-term Atorvastatin Treatment on Vaccination Efficacy in Nonresponder Persons to Hepatitis B Vaccine |
Unknown status |
NCT01548326 |
Phase 4 |
Atorvastatin;placebo |
2 |
Prophylactic Use of Entecavir to Reduce Hepatitis Flare in Highly Viremic HBV Patients With Active Tuberculosis Receiving Anti-tuberculous Treatment |
Unknown status |
NCT01724723 |
Phase 4 |
entecavir (BARACLUDE®) |
3 |
Phase IV Study of Effectiveness of Interferon and Ribavirin Treatment in Thalassemia Major Patients With Chronic Viral Hepatitis C |
Unknown status |
NCT00887081 |
Phase 4 |
PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin |
4 |
Non-randomized Prospective Study on the Effect of Antiviral Therapy With Peginterferon Alfa-2a and Ribavirin on Bone Mineral Density and Metabolism in Patients With Chronic Viral Hepatitis C Genotype 1 |
Completed |
NCT00948220 |
Phase 4 |
peginterferon alfa-2a and ribavirin |
5 |
A Multicenter, Randomized, Blinded, Placebo-controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv-1-infected Subjects Co-infected With Hepatitis C And/or Hepatitis B Virus |
Completed |
NCT01327547 |
Phase 4 |
Maraviroc;Placebo |
6 |
Pharmacovigilance Study of the Interferon α 2b Produced by Bio-Manguinhos / Fiocruz and Used by Genotype 2/3 Chronic Hepatitis C Patients (Estudo de farmacovigilância da Alfainterferona 2b Humana Recombinante Produzida Por Bio-Manguinhos - Fiocruz, Utilizada em Portadores de Hepatite C crônica genótipos 2 e 3 Atendidos Pelo Programa de Medicamentos de Dispensação em Caráter Excepcional no Estado do Rio de Janeiro) |
Completed |
NCT01841775 |
Phase 4 |
interferon α 2b + ribavirin |
7 |
Efficacy of Silymarin for Treatment of Acute Hepatitis In Egypt: A Randomized, Double-Blinded, Controlled Trial |
Completed |
NCT00412763 |
Phase 4 |
Silymarin (Silybum marianum) |
8 |
Prevention of Hepatitis B Virus (HBV) Mother-to-Child (MTC) Transmission by Serovaccination of Newborns and Use of Tenofovir DF During the Last Trimester of Pregnancy in Mothers With HBV DNA Above 100, 000 I.U/mL |
Completed |
NCT02039362 |
Phase 4 |
Tenofovir DF |
9 |
Use of Vitamin D in Treatment of Non-Alcoholic Fatty Liver Disease Detected by Transient Elastography |
Completed |
NCT04038853 |
Phase 4 |
1,25-Dihydroxyvitamin D;Placebo |
10 |
Low Dose Peginterferon and Ribavirin Therapy for Patients With Chronic Hepatitis C Infected With Genotype 2 or 3 |
Completed |
NCT00056862 |
Phase 4 |
Peginterferon alfa-2a;Peginterferon alfa-2a;Ribavirin |
11 |
A Multicenter Randomized Controlled Open-label Trial of Tenofovir vs. Tenofovir Plus Entecavir in Chronic Hepatitis B Patients With Genotypic Resistance to Entecavir and Partial Virologic Response to Ongoing Treatment |
Completed |
NCT01639092 |
Phase 4 |
Tenofovir;Tenofovir;Entecavir |
12 |
A Multicenter Randomized Controlled Open-label Trial of Tenofovir Plus Entecavir Combination vs. Tenofovir Monotherapy in Chronic Hepatitis B Patients With Genotypic Resistance to Adefovir and Partial Virologic Response to Ongoing Treatment |
Completed |
NCT01639066 |
Phase 4 |
Tenofovir;Entecavir;Tenofovir |
13 |
Prospective Detection of Liver Fibrosis With MRI Compared to Fibroscan and Blood Tests |
Completed |
NCT01600105 |
Phase 4 |
Perfusion MRI |
14 |
Pegylated Interferon Alfa-2a for Dialysis Patients With Acute Hepatitis C |
Completed |
NCT00917358 |
Phase 4 |
Pegylated interferon alfa-2a |
15 |
Comparison Between Iron Supplementation Using Total Dose Infusion and Oral Routes for Treatment of Iron Deficiency Anemia in Pregnancy |
Completed |
NCT02086838 |
Phase 4 |
Theragran Hematinic;low molecular weight iron dextran |
16 |
Clinical Trial of CNS Penetrating ART to Prevent NeuroAIDS in China |
Completed |
NCT01340950 |
Phase 4 |
zidovudine-lamivudine-nevirapine;tenofovir-lamivudine-efavirenz |
17 |
A Multicenter, Randomized, Open Label, Pilot Study to Assess the Possibility of Concomitant Treatment of HCV/HIV co Infection With Peg-interferon + Ribavirin, and Lopinavir/r as a Single Antiretroviral Agent. |
Completed |
NCT00866021 |
Phase 4 |
Lopinavir/ritonavir;Lopinavir/ritonavir with two nucleoside analogs |
18 |
A Randomized Controlled Trial of Lamivudine in Acute Hepatitis B |
Completed |
NCT00380614 |
Phase 4 |
Lamivudine |
19 |
Phase 4 Study of Recombinant Hepatitis B Vaccine in Peritoneal Dialysis Subjects |
Completed |
NCT00125775 |
Phase 4 |
|
20 |
Efficacy and Safety of Ombitasvir/ Paritaprevir / Ritonavir Plus Ribavirin in Management HCV Genotype 4 and End-stage Kidney Disease With or Without Hemodialysis (An Open Label- Multicenter Prospective Study) |
Completed |
NCT03499639 |
Phase 4 |
Ombitasvir / Paritaprevir / Ritonavir /Ribavirin Oral Tablet |
21 |
Combination of Pegylated Interferon and Ribavirin as Therapy for Patients With Chronic Hepatitis C With and Without Renal Disease |
Completed |
NCT00028093 |
Phase 4 |
Peginterferon alfa-2a with Ribavirin;Peginterferon alfa-2a |
22 |
Long-Term Therapy With Ribavirin for Chronic Hepatitis C |
Completed |
NCT00001854 |
Phase 4 |
Ribavirin |
23 |
Influence of Methylprednisolone Pulse Therapy on Liver Function in Patients With Graves' Orbitopathy |
Completed |
NCT03667157 |
Phase 4 |
every week IVMP therapy;very high doses IVMP therapy |
24 |
Comparative FK506 Drug Levels of Once Daily Advagraf in First Nations and Caucasian Patients With Liver Transplants |
Completed |
NCT04237246 |
Phase 4 |
Tacrolimus |
25 |
Pioglitazone in Hepatitis C: A Randomized, Double Blind, Placebo-controlled Study |
Completed |
NCT00189163 |
Phase 4 |
Pioglitazone;Placebo Oral Tablet |
26 |
Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B: An Open Label, Randomized Controlled Trial |
Recruiting |
NCT03933384 |
Phase 4 |
Tenofovir alafenamide;Entecavir |
27 |
Increasing Access to Hepatitis C Treatment in Opioid Endemic Rural Areas: The Kentucky Viral Hepatitis Treatment (KeY Treat) Study |
Recruiting |
NCT03949764 |
Phase 4 |
Sofosbuvir/velpatasvir (Epclusa®) |
28 |
Silymarin® - Efficacy in Treatment of Non-alcoholic Fatty Liver Disease (NAFLD) Controlled by Laboratory and and Elastographic Parameters |
Recruiting |
NCT02973295 |
Phase 4 |
Silymarin |
29 |
Efficacy and Safety of Tenofovir Alafenamide in Chronic Hepatitis B Patients With Suboptimal Response Following Nucleos(t)Ide Therapy |
Recruiting |
NCT04201808 |
Phase 4 |
Tenofovir Alafenamide 25 MG |
30 |
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection: an Open-label Randomized Clinical Trial |
Recruiting |
NCT03854630 |
Phase 4 |
Engerix-B |
31 |
Effect of Polyethylene Glycol Versus Lactulose on Hepatic Encephalopathy in Patients With Liver Cirrhosis; a Randomized Clinical Trial (PEGHE Trial) |
Recruiting |
NCT04436601 |
Phase 4 |
Polyethylene Glycols;Lactulose |
32 |
Evaluation of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Switch Followed by Sofosbuvir/Velpatasvir (SOF/VEL) Antiviral HCV Therapy Followed by Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Simplification in HIV-HCV Co-Infected Subjects on Opioid Substitution Therapy - A Pilot Feasibility Study |
Recruiting |
NCT03549312 |
Phase 4 |
Genvoya;Epclusa;Biktarvy |
33 |
An Effectiveness Trial (Phase IV) to Evaluate Protection of Pregnant Women by Hepatitis E Virus (HEV) Vaccine in Bangladesh and Risk Factors for Severe HEV Infection. |
Active, not recruiting |
NCT02759991 |
Phase 4 |
Hecolin;Hepa-B |
34 |
Towards HCV Elimination: Evaluation of an Integrated Model of HCV Care Targeting People Who Inject Drugs in Hai Phong, Vietnam |
Active, not recruiting |
NCT03537196 |
Phase 4 |
Sofosbuvir 400 mg and Daclatasvir 60 mg;Sofosbuvir 400 mg and Daclatasvir 90 mg;Ribavirin;Sofosbuvir and Daclatasvir for 24 weeks |
35 |
Expression of Inflammasomes in HCV Patients Before and After Treatment |
Not yet recruiting |
NCT04244383 |
Phase 4 |
|
36 |
RiFL:Rifaximin in Fatty Liver Disease. Does Modulation of Gut Microbiota Reduce Hepatic Inflammation in Non-Alcoholic Steatohepatitis (NASH)? |
Terminated |
NCT01355575 |
Phase 4 |
Rifaximin |
37 |
A Pilot/Feasibility Study of Ledipasvir/Sofosbuvir as Treatment for Hepatitis C in Hematopoietic Cell Transplantation (HCT) Recipients. |
Withdrawn |
NCT03279133 |
Phase 4 |
Ledipasvir 90mg/Sofosubvir 400mg |
38 |
Hepatitis C Virus Post-Exposure Prophylaxis for Health Care Workers |
Withdrawn |
NCT01766115 |
Phase 4 |
Telaprevir |
39 |
Efficacy and Safety of Continuing for a Total of 48 or Prolonging for a Total of 72 Weeks of Combined Treatment of Patients Receiving Pegasys and Copegus Who Are Biochemical Responders But Virological Non-Responders at Week 12 or Week 24 |
Unknown status |
NCT00336518 |
Phase 3 |
peginterferon alfa-2a;ribavirin |
40 |
Growth Hormone Therapy and Its Effect on Nitrogen Metabolism and Malnutrition in Liver Cirrhosis |
Unknown status |
NCT03420144 |
Phase 2, Phase 3 |
Standard Medical Therapy;Growth Hormone |
41 |
Phase III Multi-Centre Open-Label Randomized Controlled Trial of Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (SIRveNIB) |
Unknown status |
NCT01135056 |
Phase 3 |
Sorafenib tosylate |
42 |
Evaluation of Cytokine-induced Killer (CIK) Cells as Therapy or Adjuvant Treatment for Patients With Advanced Hepatocelluler Carcinoma |
Unknown status |
NCT02568748 |
Phase 3 |
|
43 |
A Decisional Algorithm to Start Iron Chelation in Minimally Transfused Young Beta-thalassemia Major Patients Naive to Iron Chelation Therapy. A Comparative Randomized Prospective Study |
Unknown status |
NCT02173951 |
Phase 2, Phase 3 |
Deferiprone |
44 |
RECURRENCE RATE OF HEPATOCELLULAR CARCINOMA AFTER TREATMENT OF CHRONIC HEPATITIS C PATIENTS WITH DIRECT ACTING ANTIVIRALS: RANDOMIZED CONTROLLED PHASE 3 TRIAL (CAUTIOUS TRIAL) |
Unknown status |
NCT03551444 |
Phase 3 |
Administration of DAA-based treatment |
45 |
Treatment of Chronic HCV Infected Egyptian Patients With Electromagnetic Waves and Herbal Therapy |
Unknown status |
NCT02215525 |
Phase 3 |
|
46 |
Health Related Quality of Life in Patient With Chronic Liver Disease and Effect of Probiotics in the Treatment of MHE and Health Related Quality of Life |
Completed |
NCT01008293 |
Phase 2, Phase 3 |
VSL#3;Lactulose |
47 |
Study of the Effects of a Sartan on Hepatic Fibrosis Progression in Chronic Viral Hepatitis C |
Completed |
NCT00265642 |
Phase 3 |
Irbesartan;placebo |
48 |
Boceprevir-based Triple Therapy to Rescue HCV Genotype 1/HBV Dually Infected Patients Refractory to Peginterferon Plus Ribavirin Combination Therapy |
Completed |
NCT02060058 |
Phase 3 |
Stop trial intervention for boceprevir, PEG-IFN and RBV |
49 |
A Randomized and Multicenter Trial for Hepatocellular Carcinoma Adjuvant Treatment by Lipiocis |
Completed |
NCT00116454 |
Phase 3 |
131 I-lipiodol |
50 |
A Randomized, Open-label Trial Comparing Telbivudine vs, Entecavir in Reducing Serum HBsAg Levels in Patients With HBeAg-positive Chronic Hepatitis B Who Have Achieved Serum HBV DNA Undetectability by Preceding Entecavir Treatment |
Completed |
NCT01595685 |
Phase 3 |
Telbivudine;Entecavir |
|